biostudies-literatureUnknown9(2)Udovicich C<h4>Importance</h4>Stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy monotherapy (HDR-BT) are options for intermediate-risk prostate cancer. However, no prospective evidence is available to compare these modalities.<h4>Objective</h4>To compare the biochemical failure (BCF), late patient-reported quality of life (PR-QoL), and acute and late adverse events (AEs) associated with SBRT and HDR-BT using prospective data.<h4>Data sources</h4>This was an individual patient data post hoc pooled analysis of 5 prospective trials with recruitment from 2010 to 2018. Statistical analyses were performed in September 2024.<h4>Study selection</h4>This was a post hoc analysis of these 5 sprospective trials. Eligibility criteria comprised men with intermediate-risk prostate cancer undergJAMA network opene260146https://www.ebi.ac.uk/biostudies/studies/S-EPMC12936880biostudies-literatureSBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.PMC12936880Ong WLMcGuffin MLoblaw AChu WDetsky JMorton GKulasingham-Poon MCheung PUdovicich CLiu SHudson JMZhang LChung HTseng CLKennedy TDeabreu AVesprini DRavi ADavidson MMamedov AHelou JfalseSBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.<h4>Importance</h4>Stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy monotherapy (HDR-BT) are options for intermediate-risk prostate cancer. However, no prospective evidence is available to compare these modalities.<h4>Objective</h4>To compare the biochemical failure (BCF), late patient-reported quality of life (PR-QoL), and acute and late adverse events (AEs) associated with SBRT and HDR-BT using prospective data.<h4>Data sources</h4>This was an individual patient data post hoc pooled analysis of 5 prospective trials with recruitment from 2010 to 2018. Statistical analyses were performed in September 2024.<h4>Study selection</h4>This was a post hoc analysis of these 5 sprospective trials. Eligibility criteria comprised men with intermediate-risk prostate cancer underg2026-01-01T00:00:00Z2026 Feb2026-07-16T22:07:50.405Z2026-07-11T03:11:51.065ZS-EPMC129368804173947010.1001/jamanetworkopen.2026.0146